微生物群、氧化三甲胺与心脏代谢疾病
Microbiome, trimethylamine N-oxide, and cardiometabolic disease.
作者信息
Tang W H Wilson, Hazen Stanley L
机构信息
Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; Center for Clinical Genomics, Cleveland Clinic, Cleveland, Ohio.
Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
出版信息
Transl Res. 2017 Jan;179:108-115. doi: 10.1016/j.trsl.2016.07.007. Epub 2016 Jul 18.
There is increasing appreciation that changes in microbiome composition and function can promote long-term susceptibility for cardiometabolic risk. Gut microbe-derived metabolites that are biologically active, such as trimethylamine N-oxide (TMAO), are now recognized as contributors to atherogenesis. This review summarizes our current understanding of the role of TMAO in the pathogenesis of cardiometabolic diseases and will discuss current findings, controversies, and further perspectives in this new area of investigation. Better appreciation of the interactions between dietary nutrient intake with gut microbiota-mediated metabolism may provide clinical insights into defining individuals at risk for disease progression in cardiometabolic diseases, as well as additional potential therapeutic targets for reducing risks for cardiometabolic disease progression.
人们越来越认识到微生物组组成和功能的变化会增加患心脏代谢疾病风险的长期易感性。肠道微生物衍生的具有生物活性的代谢产物，如氧化三甲胺（TMAO），现在被认为是动脉粥样硬化的促成因素。这篇综述总结了我们目前对TMAO在心脏代谢疾病发病机制中作用的理解，并将讨论这一新研究领域的当前发现、争议及进一步的观点。更好地理解饮食营养摄入与肠道微生物群介导的代谢之间的相互作用，可能为确定心脏代谢疾病中疾病进展风险个体提供临床见解，以及为降低心脏代谢疾病进展风险提供额外的潜在治疗靶点。
Zotero 插件